Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or

Bolt Biotherapeutics Inc (BOLT)

Bolt Biotherapeutics Inc (BOLT)
0.3200 x 10 0.3600 x 104
Post-market by (Cboe BZX)
0.3500 +0.0180 (+5.42%) 04/17/25 [NASDAQ]
0.3200 x 10 0.3600 x 104
Post-market 0.3600 +0.0100 (+2.86%) 19:00 ET
Quote Overview for Thu, Apr 17th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.3320
Day High
0.3600
Open 0.3491
Previous Close 0.3320 0.3320
Volume 35,500 35,500
Avg Vol 163,280 163,280
Stochastic %K 25.96% 25.96%
Weighted Alpha -63.06 -63.06
5-Day Change +0.0290 (+9.03%) +0.0290 (+9.03%)
52-Week Range 0.3000 - 1.3350 0.3000 - 1.3350
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,419
  • Shares Outstanding, K 38,340
  • Annual Sales, $ 7,690 K
  • Annual Income, $ -63,120 K
  • EBIT $ -76 M
  • EBITDA $ -77 M
  • 60-Month Beta 0.96
  • Price/Sales 1.66
  • Price/Cash Flow N/A
  • Price/Book 0.22
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.71
  • Most Recent Earnings $-0.38 on 03/24/25
  • Next Earnings Date 05/13/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.34
  • Number of Estimates 3
  • High Estimate -0.33
  • Low Estimate -0.35
  • Prior Year -0.28
  • Growth Rate Est. (year over year) -21.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3000 +16.67%
on 04/10/25
Period Open: 0.4101
0.4830 -27.54%
on 03/25/25
-0.0601 (-14.65%)
since 03/17/25
3-Month
0.3000 +16.67%
on 04/10/25
Period Open: 0.5126
0.5850 -40.17%
on 01/21/25
-0.1626 (-31.72%)
since 01/17/25
52-Week
0.3000 +16.67%
on 04/10/25
Period Open: 1.1100
1.3350 -73.78%
on 05/13/24
-0.7600 (-68.47%)
since 04/17/24

Most Recent Stories

More News
Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

BOLT : 0.3500 (+5.42%)
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

BOLT : 0.3500 (+5.42%)
Bolt Biotherapeutics to Participate in Upcoming March Conferences

BOLT : 0.3500 (+5.42%)
Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.

BOLT : 0.3500 (+5.42%)
Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

BOLT : 0.3500 (+5.42%)
Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

BOLT : 0.3500 (+5.42%)
Bolt Biotherapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

– BDC-1001 monotherapy and combination dose-escalation portion of the trial in HER2-expressing solid tumors on track to complete this year– New portfolio...

BOLT : 0.3500 (+5.42%)
Bolt Biotherapeutics to Present Ex Vivo Data Characterizing the Myeloid Cell Landscape in Solid Tumors at ASCO 2022

- Ex vivo data support the high frequency of myeloid cells in tumors, even when T cells are not present - REDWOOD CITY, Calif., May 27, 2022 (GLOBE...

BOLT : 0.3500 (+5.42%)
Bolt Biotherapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights

–   BDC-1001 monotherapy and OPDIVO® combination trials progressing toward data readouts in second half of 2022 –   Cash balance of $246.8 million...

BOLT : 0.3500 (+5.42%)
Bolt Biotherapeutics to Present at 21st Annual Needham Healthcare Conference

REDWOOD CITY, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new...

BOLT : 0.3500 (+5.42%)

Business Summary

Bolt Biotherapeutics Inc. is a clinical-stage immuno-oncology company. It engages in the discovery, development, and commercialization of pharmaceutical products. The company's principal product includes BDC-1001. Bolt Biotherapeutics Inc. is based in Redwood city, California.

See More

Key Turning Points

3rd Resistance Point 0.3907
2nd Resistance Point 0.3753
1st Resistance Point 0.3627
Last Price 0.3500
1st Support Level 0.3347
2nd Support Level 0.3193
3rd Support Level 0.3067

See More

52-Week High 1.3350
Fibonacci 61.8% 0.9396
Fibonacci 50% 0.8175
Fibonacci 38.2% 0.6954
Last Price 0.3500
52-Week Low 0.3000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro